Public-registry site landscape for NCT07726342, a HER2-positive Breast Cancer study sponsored by Chengdu SciMount Pharmatech Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07726342 (registry record) |
| Sponsor | Chengdu SciMount Pharmatech Co., Ltd. |
| Condition(s) | HER2-positive Breast Cancer; Metastatic Breast Cancer; Locally Advanced Breast Cancer (LABC) |
| Phase | PHASE2 |
| Listed sites | 15 |
| Site countries | China |
At The Second Affiliated Hospital of Anhui Medical University — one of the facilities listed on this trial — 14 other studies are actively recruiting HER2-positive Breast Cancer patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07726342 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →